cafusertib hydrochloride (Jiangsu Hansoh Pharmaceutical)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namecafusertib hydrochloride (Jiangsu Hansoh Pharmaceutical)
Drug Alias Namekafuseti hydrochloride (Jiangsu Hansoh Pharmaceutical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolo like kinase inhibitors
TargetsPolo like kinase
Therapy Area/IndicationsSolid tumoursLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A